Close

Mallinckrodt (MNK) Announces Presentation of OFIRMEV Injection PK Data at Annual PMM of ASRA Meeting

November 18, 2016 7:31 AM EST Send to a Friend
Mallinckrodt Pharmaceuticals (NYSE: MNK) announced results from a clinical pharmacokinetic (PK) study examining the effect of IV morphine on the ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login